"Olaparib" is an innovative drug that reduces the risk of recurrence of ovarian cancer

A recent study concluded that early treatment of ovarian cancer could reduce the chances of recurrence. Ovarian cancer is difficult to treat because most cases are diagnosed only after the spread of the disease. One-third of women live only 10 years after diagnosis. Disease.

Doctors point out that the drug called Uleaparib is the first revolutionary treatment developed in UK universities to prolong the lives of women with the disease. This medicine was administered to 260 women with BRCA. Another 135 women received alternative treatment, all undergoing surgery and some standard of chemotherapy.

According to findings published in the New England Journal of Medicine, there was no evidence of recurrence of the disease in 50% of those treated since the start of the test in 2013.

"The most interesting results are that more than half of patients treated with uleaparib have never had the disease, which is unprecedented and increases the chances of recovery from a large number of patients." between them, "said Professor Charlie Gullry of the University of Edinburgh, who led the British team in international testing. "He said.

Olaparib, sold under the trade name "Lynparza", is the first group of PARP drugs used to weaken cancer cells. It is therefore used in the treatment of women who have returned from ovarian cancer.